Opinion|Videos|September 4, 2024
Evaluating Cretostimogene: BOND-003 and PIVOT-006 Trial Results
Panelists discuss whether the trial results support investigating cretostimogene with other checkpoint inhibitors and provide insights into notable ongoing trials exploring cretostimogene for intermediate- or high-risk NMIBC, such as BOND-003 and PIVOT-006.
Advertisement
Episodes in this series
Video content above is prompted by the following questions:
- Do you think the results of this trial support the investigation of cretostimogene in combination with other checkpoint inhibitors?
- Can you briefly discuss other notable trials that are investigating cretostimogene for intermediate- or high-risk NMIBC?
Advertisement
Related to this article
Topline results are expected in November 2026 ahead of a planned sBLA submission.
In a POTOMAC subgroup analysis, durvalumab plus BCG reduced the risk of high-risk recurrence or death by 44% vs BCG alone in patients with papillary-only, BCG-naive NMIBC.
Andrea Necchi, MD, discusses how results from the CA017-078 trials compares with other perioperative immunotherapy trials in muscle-invasive bladder cancer.
Final phase 3 CA017-078 data show perioperative nivolumab plus GC did not significantly improve pCR (39.1% vs 29.6%) or EFS (HR, 0.94) vs GC alone in MIBC.
Perioperative durvalumab (Imfinzi) plus neoadjuvant enfortumab vedotin-ejfv (Padcev) cut the risk of EFS events by 49% and death by 42% in cisplatin-ineligible MIBC.
At a median follow-up of 60.9 months, median EFS was 74.1 months in the pembrolizumab arm and not reached in the placebo arm.
Michael S. Cookson, MD, MMHC, FACS, discusses how Anktiva’s expanded FDA approval may broaden bladder-preserving treatment options for BCG-unresponsive papillary-only NMIBC.
This approval expands the perioperative use of pembrolizumab plus enfortumab vedotin to all patients with MIBC, regardless of cisplatin eligibility.
Advertisement
Advertisement
Trending on Urology Times
1
Alicia Morgans, MD, MPH, highlights key prostate cancer data from ESMO 2026
2
LITESPARK-012: Lessons from a negative phase 3 trial in first-line RCC
3
ESMO 2026 recap: Notable updates across genitourinary oncology
4
Novel RIPTAC molecule shows promising activity in heavily pretreated mCRPC
5